Marcus Capital LLC lowered its holdings in shares of Celgene Co. (NASDAQ:CELG) by 42.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 6,775 shares of the biopharmaceutical company’s stock after selling 4,925 shares during the period. Marcus Capital LLC’s holdings in Celgene were worth $988,000 as of its most recent filing with the SEC.
Several other hedge funds have also added to or reduced their stakes in CELG. Thompson Davis & CO. Inc. boosted its position in Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares during the period. Arcadia Investment Management Corp MI boosted its position in Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares during the period. Guidant Wealth Advisors purchased a new stake in Celgene during the 3rd quarter valued at $119,000. Motco boosted its position in Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 159 shares during the period. Finally, Penserra Capital Management LLC purchased a new stake in Celgene during the 2nd quarter valued at $129,000. 79.85% of the stock is currently owned by institutional investors.
Shares of Celgene Co. (CELG) traded up $0.93 during mid-day trading on Friday, hitting $102.65. 7,714,583 shares of the stock were exchanged, compared to its average volume of 6,700,000. Celgene Co. has a 52-week low of $94.55 and a 52-week high of $147.17. The company has a market capitalization of $80,820.00, a price-to-earnings ratio of 24.21, a PEG ratio of 0.66 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same period in the previous year, the business posted $1.58 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. sell-side analysts forecast that Celgene Co. will post 6.71 EPS for the current year.
Several equities research analysts have weighed in on the stock. BidaskClub cut shares of Celgene from a “hold” rating to a “sell” rating in a research report on Saturday. Piper Jaffray Companies reissued a “hold” rating and set a $104.00 price target on shares of Celgene in a research report on Thursday. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $114.80 target price for the company in a research report on Wednesday. Cantor Fitzgerald set a $112.00 target price on shares of Celgene and gave the stock a “hold” rating in a research report on Wednesday. Finally, Mizuho reaffirmed a “buy” rating and issued a $128.00 target price on shares of Celgene in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. Celgene currently has an average rating of “Buy” and an average price target of $129.98.
WARNING: “Marcus Capital LLC Reduces Position in Celgene Co. (NASDAQ:CELG)” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/01/21/celgene-co-celg-stake-lowered-by-marcus-capital-llc.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.